Catalyst Event

Sanofi (SNY) · Other

From KEDI Palantir Fixed Tech100 Index (KPLTT100)

5/29/2026, 12:00:00 AM

OtherSentiment: Positive

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization on May 29, 2026, for rilzabrutinib (Wayrilz) to treat adults with immune thrombocytopenia (ITP).

Korean Translation

영국 의약품 및 의료기기 규제청(MHRA), 2026년 5월 29일 성인 면역성 혈소판 감소증(ITP) 치료제로 릴자브루티닙(상표명 웨이릴즈)의 판매를 승인함.

Related Recent Events

View Full Timeline